Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression

International Journal of Neuropsychopharmacology

Volumn 7, Issue 3, 2004, Pages 341-349

  Murck, Harald ^a   Song, Cai ^b   Horrobin, David F ^a   Uhr, Manfred ^c  

^a Laxdale Ltd   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Eicosapentaenoic acid; HPA axis; Melancholic; p glycoprotein; Peroxisome proliferator activated receptor; Therapy refractory depression

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CLOMIPRAMINE; DESIPRAMINE; DEXAMETHASONE; FLUOXETINE; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLYCOPROTEIN P; HYDROCORTISONE; ICOSAPENTAENOIC ACID ETHYL ESTER; INTERLEUKIN 12; INTERLEUKIN 6; MIFEPRISTONE; OMEGA 3 FATTY ACID; PAROXETINE; PROSTAGLANDIN E2; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADD ON THERAPY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE EFFECT; LEUKOCYTE COUNT; MELANCHOLIA; MONOTHERAPY; MULTIDRUG RESISTANCE; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THERAPY REFRACTORY DEPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CD4-CD8 RATIO; DEPRESSIVE DISORDER, MAJOR; DEXAMETHASONE; DRUG RESISTANCE; EICOSAPENTAENOIC ACID; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; LEUKOCYTE COUNT; PITUITARY-ADRENAL SYSTEM; PSYCHIATRIC STATUS RATING SCALES;

EID: 4444363691     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004249     Document Type: Review

References (84)

1. Adams PB, Lawson S, Sanigorski A, Sinclair AJ (1996). Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31, S157-S161.
2. Antonijevic IA, Murck H, Frieboes RM, Steiger A (2000). Sexually dimorphic effects of GHRH on sleep-endocrine activity in patients with depression and normal controls - Part II: Hormone secretion. Sleep Research Online 3, 15-21.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
4. Armstrong MB, Towle HC (2001). Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalpha-mediated pathway. American Journal of Physiology 281, E1197-1204.
5. Barocka A, Pichl J, Beck G, Rupprecht R (1987). Factors interfering with the 1 mg dexamethasone suppression test in depression. Pharmacopsychiatry 20, 258-261.
6. Cairncross KD, Wren A, Cox B, Schnieden H (1977). Effects of olfactory bulbectomy and domicile on stress-induced corticosterone release in the rat. Physiology and Behavior 19, 485-487.
7. Calder PC (2002). Dietary modification of inflammation with lipids. Proceedings of the Nutrition Society 61, 345-358.
8. Carroll BJ (1982). The dexamethasone suppression test for melancholia. British Journal of Psychiatry 140, 292-304.
9. Casper RC, Swann AC, Stokes PE, Chang S, Katz MM, Garver D (1987). Weight loss, cortisol levels, and dexamethasone suppression in major depressive disorder. Acta Psychiatrica Scandinavica 75, 243-250.
10. Chambers TC, Zheng B, Kuo JF (1992). Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Molecular Pharmacology 41, 1008-1015.
11. Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H (2002). Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obesity Research 10, 518-525.
12. Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P (1998). Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites? Prostaglandins Leukotrienes and Essential Fatty Acids 58, 39-54.
13. Edwards R, Peet M, Shay J, Horrobin D (1998). Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders 48, 149-155.
14. Elenkov IJ, Chrousos GP (1999). Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends in Endocrinology and Metabolism 10, 359-368.
15. Engblom D, Ek M, Saha S, Ericsson-Dahlstrand A, Jakobsson PJ, Blomqvist A (2002). Prostaglandins as inflammatory messengers across the blood-brain barrier. Journal of Molecular Medicine 80, 5-15.
16. Frank M, Denton M, Alexander S, Khoury S, Sayegh M, Briscoe D (2001). Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. Journal of Immunology 166, 2451-2459.
17. Gold PW, Chrousos GP (1998). The endocrinology of melancholic and atypical depression: relation to neurocircuity and somatic consequences. Proceedings of the Association of American Physicians 111, 22-34.
18. Haak E, Usadel KH, Kusterer K, Amini P, Frommeyer R, Tritschler HJ, Haak T (2000). Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Experimental and Clinical Endocrinology and Diabetes 108, 168-174.
19. Hayley S, Merali Z, Anisman H (2002). The acute and sensitization effects of tumor necrosis factor-alpha: implications for the immunotherapy as well as psychiatric and neurological conditions. Acta Neuropsychiatrica 14, 322-335.
20. Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Nemeroff CB, Holsboer F (1998). Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depression and Anxiety 8, 71-79.
21. Holsboer F, Philipp M, Steiger A, Gerken A (1986a). Multisteroid analysis after DST in depressed patients - a controlled study. Journal of Affective Disorders 10, 241-249.
22. Holsboer F, von Bardeleben U, Steiger A (1988). Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology 48, 32-38.
23. Holsboer F, Wiedemann K, Boll E (1986b). Shortened dexamethasone half-life in depressed dexamethasone nonsuppressors. Archives of General Psychiatry 43, 813-815.
24. Horrobin DF, Jenkins K, Bennett CN, Christie WW (2002). Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukotrienes and Essential Fatty Acids 66, 83-90.
25. Hsu SY, Hsueh AJ (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 7, 605-611.
26. Hubain PP, Staner L, Dramaix M, Kerkhofs M, Papadimitriou G, Mendlewicz J, Linkowski P (1998). The dexamethasone suppression test and sleep electroencephalogram in nonbipolar major depressed inpatients: a multivariate analysis. Biological Psychiatry 43, 220-229.
27. Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, Hsi LC, Eling TE (2001). Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Experimental Cell Research 267, 73-80.
28. Inoue I, Shino K, Noji S, Awata T, Katayama S (1998). Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochemical and Biophysical Research Communications 246, 370-374.
29. Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, de Kloet ER (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142, 2686-2694.
30. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ (2002a). Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Research 941, 1-10.
31. Kim HFS, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB (2001). Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Molecular Psychiatry 6, 246-248.
32. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, Licinio J (2002b). The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Molecular Psychiatry 7, 1107-1114.
33. Klein A, Bruser B, Malkin A (1989). The effect of fatty acids on the vulnerability of lymphocytes to cortisol. Metabolism: Clinical and Experimental 38, 278-281,
34. Koyama Y, Mizobata T, Yamamoto N, Hashimoto H, Matsuda T, Baba A (1999). Endothelins stimulate expression of cyclooxygenase 2 in rat cultured astrocytes. Journal of Neurochemistry 73, 1004-1011
35. Licinio J, Wong ML (1999). The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems and contribute to neurotoxicity and neuroprotection. Molecular Psychiatry 4, 317-327.
36. Lisansky J, Fava GA, Zielezny MA, Morphy MA, Kellner R (1987). Nocturnal prolactin and cortisol secretion and recovery from melancholia. Psychoneuroendocrinology 12, 303-311.
37. Lo CJ, Chiu KC, Fu MJ, Lo R, Helton S (1999). Fish oil augments macrophage cyclooxygenase II (COX-2) gene expression induced by endotoxin. Journal of Surgical Research 86, 103-107.
38. Maes M (1995). Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry 19, 11-38.
39. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E (1993). Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? American Journal of Psychiatry 150, 1189-1193.
40. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999). Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Research 85, 275-291.
41. Maes M, De Ruyter M, Hobin P, Suy E (1986). The dexamethasone suppression test, the Hamilton Depression Rating Scale and the DSM-III depression categories. Journal of Affective Disorders 10, 207-214.
42. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J (1992a). Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychological Medicine 22, 45-53.
43. Maes M, Maes L, Suy E (1990). Symptom profiles of biological markers in depression: a multivariate study. Psychoneuroendocrinology 15, 29-37.
44. Maes M, Van der Planken M, Stevens WJ, Peeters D, DeClerck LS, Bridts CH, Schotte C, Cosyns P (1992b). Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression. Journal of Psychiatric Research 26, 125-134.
45. Miller KB, Nelson JC (1987). Does the dexamethasone suppression test relate to subtypes, factors, symptoms, or severity? Archives of General Psychiatry 44, 769-774.
46. Monville C, Fages C, Feyens AM, D'Hondt V, Guillet C, Vernallis A, Gascan H, Peschanski M (2002). Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF. BMC Cell Biology 3, 20.
47. Müller MB, Keck ME, Binder EB, Kresse AE, Hagemayer TP, Landgraf R, Holsboer F, Uhr M (2003). ABCB1 (MDR1)-type P-glycoprotein at the blood-brain barrier modulate the activity of the hypothamalic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28, 1991-1999.
48. Murck H (2003). Atypical depression spectrum disorder - neurobiology and treatment. Acta Neuropsychiatrica 15, 227-241.
49. Nasr SJ, Gibbons RD (1983). Depressive symptoms associated with dexamethasone resistance. Psychiatry Research 10, 183-189.
50. Nelson WH, Orr Jr. WW, Stevenson JM, Shane SR (1982). Hypothalamic-pituitary-adrenal axis activity and tricyclic response in major depression. Archives of General Psychiatry 39, 1033-1036.
51. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226, 1342-1344.
52. Nemets B, Stahl Z, Belmaker RH (2002). Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry 159, 477-479.
53. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C (1999). Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. Journal of Neuroendocrinology 11, 887-895.
54. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, Kerwin RW (2001). Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. British Journal of Pharmacology 134, 1335-1343.
55. Parker G (2001). 'New' and 'old' antidepressants: all equal in the eyes of the lore? British Journal of Psychiatry 179, 95-96.
56. Peet M, Horrobin DF (2002). A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry 59, 913-919.
57. Peet M, Horrobin DF, EPA Multicentre Study Group (2002). A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36, 7-18.
58. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, Tangrea JA (2001). Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; Is chemoprevention against multidrug resistance possible? Anticancer Research 21, 2141-2147.
59. Roose SP, Glassman AH, Attia E, Woodring S (1994). Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 151, 1735-1739.
60. Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H (2001). Inflammatory markers in major depression and melancholia. Journal of Affective Disorders 63, 93-102.
61. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker Jr. CR, Weissenburger JE, Crowley GT, Khatami M, Vasavada N (1996). The dexamethasone suppression test in patients with mood disorders. Journal of Clinical Psychiatry 57, 470-484.
62. Sapolsky RM (2000). The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biological Psychiatry 48, 755-765.
63. Sethi S, Ziouzenkova O, Ni HY, Wagner DD, Plutzky J, Mayadas TN (2002). Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothehal interactions through activation of PPARalpha. Blood 100, 1340-1346.
64. Song C (2000). The interaction between cytokines and neurotransmitters in depression and stress: possible mechanisms of antidepressant treatments. Human Psychopharmacology 15, 199-211.
65. Song C (2002). The effect of thymectomy and IL-1 on memory: implications for the relationship between immunity and depression. Brain, Behavior, and Immunity 16, 557-568.
66. Song C, Leonard BE (1995). The effect of olfactory bulbectomy in the rat, alone or in combination with antidepressants and endogenous factors, on immune function. Human Psychopharmacology 10, 7-18.
67. Song C, Li XW, Leonard BE, Horrobin DF (2003). Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. Journal of Lipid Research 44, 1984-1991.
68. Steckler T, Holsboer F (1999). Corticotropin-releasing hormone receptor subtypes and emotion. Biological Psychiatry 46, 1480-1508.
69. Thase ME (1998). Depression, sleep, and antidepressants. Journal of Clinical Psychiatry 59 (Suppl. 4), 55-65.
70. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. Journal of Biological Chemistry 267, 24248-24252.
71. Uhr M, Grauer MT (2003). abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. Journal of Psychiatric Research 37, 179-185.
72. Uhr M, Holsboer F, Muller MB (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. Journal of Neuroendocrinology 14, 753-759.
73. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22, 380-387.
74. Vallette G, Sumida C, Thobie N, Nunez EA (1995). Unsaturated fatty acids synergistically enhance glucocorticoid-induced gene expression. Cellular Signalling 7, 319-323.
75. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J, Ocsovszky I, Molnar J (1996). Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Research 16, 209-211.
76. Vine DF, Charman SA, Gibson PR, Sinclair AJ, Porter CJH (2002). Effect of dietary fatty acids on the intestinal permeability of marker drug compounds in excised rat jejunum. Journal of Pharmacy and Pharmacology 54, 809-819.
77. Wiedemann K, Holsboer F (1987). Plasma dexamethasone kinetics during the DST after oral and intravenous administration of the test drug. Biological Psychiatry 22, 1340-1348.
78. Wodarz N, Rupprecht R, Kornhuber J, Schmitz B, Wild K, Braner HU, Riederer P (1991). Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. Journal of Affective Disorders 22, 241-248.
79. Wolkowitz OM, Reus VI (1999). Treatment of depression with antiglucocorticoid drugs. Psychosomatic Medicine 61, 698-711.
80. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti Jr. TD, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW (2000). Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proceedings of the National Academy of Sciences USA 97, 325-330.
81. Yang WL, Frucht H (2001). Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22, 1379-1383.
82. Yehuda S, Rabinovitz S, Carasso RL, Mostofsky DI (2000). Fatty acid mixture counters stress changes in cortisol, cholesterol, and impair learning. International Journal of Neuroscience 101, 73-87.
83. Ziemann C, Schafer D, Rudell G, Kahl GF, Hirsch-Ernst KI (2002). The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 35, 579-588.
84. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001). The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain, Behavior, and Immunity 15, 199-226.